Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: Results from Val-HeFT

Henry Krum, Peter Carson, Csaba Farsang, Aldo P. Maggioni, Robert D. Glazer, Nora Aknay, Yann Tong Chiang, Jay N. Cohn

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF). Subjects in Val-HeFT receiving ACEi but not beta-blocker at baseline were analysed; 1532 were assigned to valsartan and 1502 assigned to placebo. Primary outcome events (all-cause mortality, hospitalisation for adjudicated heart failure, sudden death with resuscitation and need for >4 h of parenteral therapy for worsening heart failure) were monitored. Mortality was not affected by valsartan but morbidity endpoints were significantly reduced (36.3% in placebo, 31.0% in valsartan, p=0.002) in patients receiving an ACEi but no beta-blocker. Quality of life (QOL) was significantly improved, ejection fraction (EF) significantly increased, left ventricular (LV) diameter significantly reduced and plasma B-type natriuretic peptide, norepinephrine and aldosterone levels significantly reduced with valsartan compared to placebo. The morbidity benefit was significant in patients on ACEi doses below the median (22% reduction, p=0.003) and not statistically significant in those receiving ACEi doses above the median (14% reduction, p=0.143). Valsartan reduces heart failure hospitalisations and slows LV remodelling in patients treated with an ACEi in the absence of beta-blockade, particularly in those on lower doses of ACEi.

Original languageEnglish (US)
Pages (from-to)937-945
Number of pages9
JournalEuropean Journal of Heart Failure
Volume6
Issue number7
DOIs
StatePublished - Dec 1 2004

Fingerprint

Valsartan
Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Placebos
Therapeutics
Hospitalization
Morbidity
Ventricular Remodeling
Mortality
Brain Natriuretic Peptide
Sudden Death
Aldosterone
Resuscitation

Keywords

  • ACE-inhibition
  • Angiotensin receptor blockade
  • Chronic heart failure
  • Mortality
  • Valsartan

Cite this

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure : Results from Val-HeFT. / Krum, Henry; Carson, Peter; Farsang, Csaba; Maggioni, Aldo P.; Glazer, Robert D.; Aknay, Nora; Chiang, Yann Tong; Cohn, Jay N.

In: European Journal of Heart Failure, Vol. 6, No. 7, 01.12.2004, p. 937-945.

Research output: Contribution to journalArticle

Krum, Henry ; Carson, Peter ; Farsang, Csaba ; Maggioni, Aldo P. ; Glazer, Robert D. ; Aknay, Nora ; Chiang, Yann Tong ; Cohn, Jay N. / Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure : Results from Val-HeFT. In: European Journal of Heart Failure. 2004 ; Vol. 6, No. 7. pp. 937-945.
@article{8b884ae7e64e4d6aa867e1d036fccb89,
title = "Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: Results from Val-HeFT",
abstract = "To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF). Subjects in Val-HeFT receiving ACEi but not beta-blocker at baseline were analysed; 1532 were assigned to valsartan and 1502 assigned to placebo. Primary outcome events (all-cause mortality, hospitalisation for adjudicated heart failure, sudden death with resuscitation and need for >4 h of parenteral therapy for worsening heart failure) were monitored. Mortality was not affected by valsartan but morbidity endpoints were significantly reduced (36.3{\%} in placebo, 31.0{\%} in valsartan, p=0.002) in patients receiving an ACEi but no beta-blocker. Quality of life (QOL) was significantly improved, ejection fraction (EF) significantly increased, left ventricular (LV) diameter significantly reduced and plasma B-type natriuretic peptide, norepinephrine and aldosterone levels significantly reduced with valsartan compared to placebo. The morbidity benefit was significant in patients on ACEi doses below the median (22{\%} reduction, p=0.003) and not statistically significant in those receiving ACEi doses above the median (14{\%} reduction, p=0.143). Valsartan reduces heart failure hospitalisations and slows LV remodelling in patients treated with an ACEi in the absence of beta-blockade, particularly in those on lower doses of ACEi.",
keywords = "ACE-inhibition, Angiotensin receptor blockade, Chronic heart failure, Mortality, Valsartan",
author = "Henry Krum and Peter Carson and Csaba Farsang and Maggioni, {Aldo P.} and Glazer, {Robert D.} and Nora Aknay and Chiang, {Yann Tong} and Cohn, {Jay N.}",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.ejheart.2004.09.005",
language = "English (US)",
volume = "6",
pages = "937--945",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure

T2 - Results from Val-HeFT

AU - Krum, Henry

AU - Carson, Peter

AU - Farsang, Csaba

AU - Maggioni, Aldo P.

AU - Glazer, Robert D.

AU - Aknay, Nora

AU - Chiang, Yann Tong

AU - Cohn, Jay N.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF). Subjects in Val-HeFT receiving ACEi but not beta-blocker at baseline were analysed; 1532 were assigned to valsartan and 1502 assigned to placebo. Primary outcome events (all-cause mortality, hospitalisation for adjudicated heart failure, sudden death with resuscitation and need for >4 h of parenteral therapy for worsening heart failure) were monitored. Mortality was not affected by valsartan but morbidity endpoints were significantly reduced (36.3% in placebo, 31.0% in valsartan, p=0.002) in patients receiving an ACEi but no beta-blocker. Quality of life (QOL) was significantly improved, ejection fraction (EF) significantly increased, left ventricular (LV) diameter significantly reduced and plasma B-type natriuretic peptide, norepinephrine and aldosterone levels significantly reduced with valsartan compared to placebo. The morbidity benefit was significant in patients on ACEi doses below the median (22% reduction, p=0.003) and not statistically significant in those receiving ACEi doses above the median (14% reduction, p=0.143). Valsartan reduces heart failure hospitalisations and slows LV remodelling in patients treated with an ACEi in the absence of beta-blockade, particularly in those on lower doses of ACEi.

AB - To investigate the effect of valsartan in the Valsartan-Heart Failure Trial (Val-HeFT) when added to angiotensin-converting enzyme inhibitor (ACEi) alone in patients with heart failure (HF). Subjects in Val-HeFT receiving ACEi but not beta-blocker at baseline were analysed; 1532 were assigned to valsartan and 1502 assigned to placebo. Primary outcome events (all-cause mortality, hospitalisation for adjudicated heart failure, sudden death with resuscitation and need for >4 h of parenteral therapy for worsening heart failure) were monitored. Mortality was not affected by valsartan but morbidity endpoints were significantly reduced (36.3% in placebo, 31.0% in valsartan, p=0.002) in patients receiving an ACEi but no beta-blocker. Quality of life (QOL) was significantly improved, ejection fraction (EF) significantly increased, left ventricular (LV) diameter significantly reduced and plasma B-type natriuretic peptide, norepinephrine and aldosterone levels significantly reduced with valsartan compared to placebo. The morbidity benefit was significant in patients on ACEi doses below the median (22% reduction, p=0.003) and not statistically significant in those receiving ACEi doses above the median (14% reduction, p=0.143). Valsartan reduces heart failure hospitalisations and slows LV remodelling in patients treated with an ACEi in the absence of beta-blockade, particularly in those on lower doses of ACEi.

KW - ACE-inhibition

KW - Angiotensin receptor blockade

KW - Chronic heart failure

KW - Mortality

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=8844239987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844239987&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2004.09.005

DO - 10.1016/j.ejheart.2004.09.005

M3 - Article

C2 - 15556056

AN - SCOPUS:8844239987

VL - 6

SP - 937

EP - 945

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 7

ER -